Annovis Bio shares rise 2.06% in premarket after positive clinical results for Buntanetap in Alzheimer's and Parkinson's disease trials.

Annovis Bio, Inc. surged 2.06% in premarket trading, as its lead drug candidate Buntanetap showed reduced levels of neurotoxic proteins in Alzheimer's and Parkinson's patients, improving axonal transport and reducing neuronal death. The company's clinical-stage drug Buntanetap, which inhibits the translation of multiple neurotoxic proteins, demonstrated potential efficacy in treating neurodegenerative diseases, driving stock price movement.